The stock's rise snapped a three-day losing streak.

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same ...

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

Vertex Pharmaceuticals Inc. closed 5.23% below its 52-week high of $519.88, which the company achieved on November 8th.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Among the largest underlying components of IVW, in trading today Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is off about 0.8%, Fiserv Inc (Symbol: FI) is up about 1%, and GE Vernova Inc (Symbol ...

Vertex Pharmaceuticals dominates the market for ... Sionna’s shares debuted on the Nasdaq Friday under the stock symbol “SION.” Strong investor interest in the new stock enabled Sionna ...

Danaher Corp (Symbol: DHR) is up about 1.9%, and Vertex Pharmaceuticals, Inc. (Symbol: VRTX) is higher by about 0.1%. For a complete list of holdings, visit the XLV Holdings page » The chart ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...